Mount Sinai Hospital: FDA Approves Mirikizumab, a Promising Induction, Maintenance Therapy for Ulcerative Colitis
October 31, 2023
October 31, 2023
NEW YORK, Oct. 31 (TNSres) -- Mount Sinai Hospital issued the following news release:
The U.S. Food and Drug Administration (FDA) approved mirikizumab, on October 26, 2023, a highly effective new treatment for ulcerative colitis (UC), offering a new option to patients battling this chronic and debilitating inflammatory bowel disease.
This therapy offers a safe and effective treatment option for patients with moderate-to-severely active UC who have yet to achieve rapid a . . .
The U.S. Food and Drug Administration (FDA) approved mirikizumab, on October 26, 2023, a highly effective new treatment for ulcerative colitis (UC), offering a new option to patients battling this chronic and debilitating inflammatory bowel disease.
This therapy offers a safe and effective treatment option for patients with moderate-to-severely active UC who have yet to achieve rapid a . . .